Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of TAK-438 maintenance in healed erosive esophagitis
NCT01452776Phase 3Completed
- Sponsor
- Takeda
- Start
- Sep 2011
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of vonoprazan in erosive esophagitis (EE) (2 arms), sponsored by Takeda. Primary endpoint: Incidence of Treatment-emergent Adverse Events at 52 weeks. Started Sep 2011; status: completed.
02
Drugs
vonoprazan
03
Conditions
erosive esophagitis (EE)
Beyond the preview
Go deeper on NCT01452776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01452776.